KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2016 - 2025)

Abbott Laboratories' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $370.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 8.19% year-over-year to $370.0 million; the TTM value through Dec 2025 reached $1.4 billion, up 7.01%, while the annual FY2025 figure was $1.4 billion, 7.01% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $370.0 million at Abbott Laboratories, roughly flat from $371.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $425.0 million in Q1 2021 and bottomed at $302.0 million in Q2 2023.
  • The 5-year median for Depreciation & Amortization (CF) is $332.5 million (2023), against an average of $339.8 million.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 59.18% in 2021 before it dropped 26.82% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $369.0 million in 2021, then dropped by 15.72% to $311.0 million in 2022, then rose by 6.75% to $332.0 million in 2023, then grew by 3.01% to $342.0 million in 2024, then rose by 8.19% to $370.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Depreciation & Amortization (CF) are $370.0 million (Q4 2025), $371.0 million (Q3 2025), and $357.0 million (Q2 2025).